Inflammatory Burden Index As a Prognostic Marker in Patients with Advanced Gastric Cancer Treated with Neoadjuvant Chemotherapy and Immunotherapy

Overview

Journal Front Immunol

Date 2025 Feb 5

PMID 39906738

Authors

Jiao-Bao Huang

Zhi-Yong Zhou

Jun Lu

Ji-Yun Zhu

Bin Lai

Sheng-Xun Mao

Jia-Qing Cao

Affiliations

Soon will be listed here.

Abstract

Background: Blood inflammation index has been shown to correlate with the prognosis of patients with gastric cancer. However, few studies have compared the efficacy of existing blood inflammatory markers in predicting the prognosis of patients with locally advanced gastric cancer in combination with neoadjuvant chemotherapy and immunotherapy.

Objective: The objective of this study was to compare the prognostic value of existing commonly used blood inflammatory index in patients with advanced gastric cancer treated with neoadjuvant chemotherapy combined with immunotherapy.

Methods: The clinicopathological data of patients with advanced gastric cancer from three centers in China were analyzed retrospectively. Univariate COX regression analysis was used to analyze the independent risk factors of poor tumor regression and overall survival (OS) in this part of patients, and the predictive value of different inflammatory indexes on prognosis was compared by C-index index. Finally, Inflammatory burden index(IBI) was grouped by X-tile software, and Kaplan-Meier method was used to compare the survival difference between groups.

Results: A total of 163 patients were enrolled in this study. The median age was 63 years(56-68). The median cycle of neoadjuvant therapy was 4(3-4). The median survival time was 85.1%(1 years), 65.6%(2 years), and 47.4%(3 years).Univariate analysis showed that IBI was an independent risk factor for non-TR(residual tumor cells>50%) (HR=1.08,95%CI:1.00-1.45,p<0.001)and OS(HR=1.04,95%CI:1.03-1.05,p<0.001). IBI is the best predictor of OS (C-index: 0.82, 95% CI: 0.78-0.87) among all inflammatory indexes. The IBI cutoff value was 52.1. It was found that the high IBI group had a higher incidence of postoperative complications(32.1%vs14.3%, p=0.001), the proportion of non-TR patients was significantly higher than that of the low IBI group(64.3%vs35.7%, p =0.001), and the high IBI group had a significantly lower OS((47.6% vs 87.6%, p < 0.001).

Conclusion: IBI is the best inflammatory index to predict the prognosis of advanced gastric cancer treated with neoadjuvant chemotherapy combined with immunotherapy, which will help guide patients' treatment decisions. This result still needs to be verified by large prospective studies.

References

Ameratunga M, Chenard-Poirier M, Candilejo I, Pedregal M, Lui A, Dolling D . Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. Eur J Cancer. 2017; 89:56-63. DOI: 10.1016/j.ejca.2017.11.012. View

Xie H, Zhang Q, Ruan G, Ge Y, Hu C, Song M . Evaluation and Validation of the Prognostic Value of Serum Albumin to Globulin Ratio in Patients With Cancer Cachexia: Results From a Large Multicenter Collaboration. Front Oncol. 2021; 11:707705. PMC: 8461248. DOI: 10.3389/fonc.2021.707705. View

Becker K, Langer R, Reim D, Novotny A, Zum Buschenfelde C, Engel J . Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011; 253(5):934-9. DOI: 10.1097/SLA.0b013e318216f449. View

Song M, Zhang Q, Song C, Liu T, Zhang X, Ruan G . The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer. J Cachexia Sarcopenia Muscle. 2022; 13(5):2504-2514. PMC: 9530543. DOI: 10.1002/jcsm.13032. View

De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S . A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 2005; 92(9):1644-9. PMC: 2362040. DOI: 10.1038/sj.bjc.6602573. View

Daud A, Wolchok J, Robert C, Hwu W, Weber J, Ribas A . Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016; 34(34):4102-4109. PMC: 5562434. DOI: 10.1200/JCO.2016.67.2477. View

Qin H, Wei G, Gwak D, Dong Z, Xiong A, Kwak L . Targeting tumor-associated myeloid cells for cancer immunotherapy. Oncoimmunology. 2015; 4(3):e983961. PMC: 4404802. DOI: 10.4161/2162402X.2014.983761. View

Binnewies M, Roberts E, Kersten K, Chan V, Fearon D, Merad M . Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018; 24(5):541-550. PMC: 5998822. DOI: 10.1038/s41591-018-0014-x. View

Xie H, Ruan G, Ge Y, Zhang Q, Zhang H, Lin S . Inflammatory burden as a prognostic biomarker for cancer. Clin Nutr. 2022; 41(6):1236-1243. DOI: 10.1016/j.clnu.2022.04.019. View

10.

Camp R, Dolled-Filhart M, Rimm D . X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10(21):7252-9. DOI: 10.1158/1078-0432.CCR-04-0713. View

11.

Greten F, Grivennikov S . Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019; 51(1):27-41. PMC: 6831096. DOI: 10.1016/j.immuni.2019.06.025. View

12.

Felix K, Gaida M . Neutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor Progression. Int J Biol Sci. 2016; 12(3):302-13. PMC: 4753159. DOI: 10.7150/ijbs.14996. View

13.

McMillan D . Cancer and systemic inflammation: stage the tumour and stage the host. Br J Cancer. 2013; 109(3):529. PMC: 3738113. DOI: 10.1038/bjc.2013.418. View

14.

Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K . Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol. 2009; 21(5):1001-5. DOI: 10.1093/annonc/mdp464. View

15.

Lin J, Lin J, Xie J, Wang J, Lu J, Chen Q . Prognostic importance of the preoperative modified systemic inflammation score for patients with gastric cancer. Gastric Cancer. 2018; 22(2):403-412. DOI: 10.1007/s10120-018-0854-6. View

16.

Ding P, Wu H, Liu P, Sun C, Yang P, Tian Y . The inflammatory burden index: A promising prognostic predictor in patients with locally advanced gastric cancer. Clin Nutr. 2023; 42(2):247-248. DOI: 10.1016/j.clnu.2023.01.005. View

17.

Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Ide S, Kitajima T . Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer. Ann Surg. 2020; 272(2):342-351. DOI: 10.1097/SLA.0000000000003239. View

18.

Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R . Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024; 4(1):47-53. PMC: 11256708. DOI: 10.1016/j.jncc.2024.01.006. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

van t Land F, Aziz M, Michiels N, Mieog J, Bonsing B, Luelmo S . Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, Multicenter, Cohort Study. Ann Surg. 2023; 278(6):1018-1023. PMC: 10631500. DOI: 10.1097/SLA.0000000000005865. View